Ionis
Ionis Claims Curative Potential for Tryngolza in Severe Triglyceride Disease
Ionis; Tryngolza; severe hypertriglyceridemia; curative potential; triglyceride reduction; acute pancreatitis; antisense oligonucleotide; FDA submission; Phase III trial; RNA-targeted therapy
FDA Action Alert: Recent Developments on Unapproved Drugs and Prescription Drug Approvals
FDA Action Alert, Unapproved Drugs, Prescription Drug Approvals, Azurity Pharmaceuticals Inc., Bristol Myers Squibb, Ionis, Lexicon
Biogen and Ionis’ ALS Treatment Qalsody Receives European Commission Approval
Biogen, Ionis, Qalsody, ALS, European Commission, Marketing Authorization, Rare Disease, SOD1-ALS, Neurofilament, Clinical Trials
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.
Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials
Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.